AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Seekingalpha

Published November 3, 2026 · Updated November 4, 2026

COMPASS Pathways stock rebounds after earnings (CMPS: NASDAQ) - Seeking Alpha

Read the full story at Seekingalpha

psychedelic therapy. U.K.-based biotech lost more than 27%, and its listed peers such as Helus Pharma (HELP), Definium Therapeutics (DFTX), and GH.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech